Overview

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

Status:
Completed
Trial end date:
2021-03-19
Target enrollment:
0
Participant gender:
All
Summary
To investigate the hemodynamic effects of PACAP38 after glibenclamide administration.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Danish Headache Center
Treatments:
Glyburide
Pituitary Adenylate Cyclase-Activating Polypeptide
Criteria
Inclusion Criteria:

- Healthy volunteers of both sexes.

- 18-60 years.

- 50-100 kg.

- Women of childbearing age must use adequate contraception

Exclusion Criteria:

- A history of serious somatic or psychiatric disease

- Migraine or any other type of headache (except episodic tension-type headache less
than 5 days per month)

- Daily intake of any medication except contraceptives